Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 179.9x - 198.9x | 189.4x |
| Selected Fwd Ps Multiple | 119.3x - 131.9x | 125.6x |
| Fair Value | $0.19 - $0.21 | $0.20 |
| Upside | -12.3% - -3.1% | -7.7% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Fate Therapeutics, Inc. | - | NasdaqGM:FATE |
| Capricor Therapeutics, Inc. | - | NasdaqCM:CAPR |
| Fortress Biotech, Inc. | - | NasdaqCM:FBIO |
| Perspective Therapeutics, Inc. | - | NYSEAM:CATX |
| Plus Therapeutics, Inc. | - | NasdaqCM:PSTV |
| Northwest Biotherapeutics, Inc. | - | OTCPK:NWBO |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| FATE | CAPR | FBIO | CATX | PSTV | NWBO | |||
| NasdaqGM:FATE | NasdaqCM:CAPR | NasdaqCM:FBIO | NYSEAM:CATX | NasdaqCM:PSTV | OTCPK:NWBO | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 5.0% | 85.8% | 25.7% | -27.6% | 10.5% | -10.5% | ||
| 3Y CAGR | -37.5% | 349.7% | 22.8% | -47.5% | 153.1% | 11.2% | ||
| Latest Twelve Months | -78.5% | -11.5% | -31.8% | 1.4% | 18.5% | -28.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -711.1% | -2863.2% | -237.7% | -1261.5% | -3222.1% | -7646.8% | ||
| Prior Fiscal Year | -253.3% | -88.5% | -124.9% | -2611.9% | -9051.3% | -3331.9% | ||
| Latest Fiscal Year | -1366.5% | -181.7% | -81.3% | -5387.2% | -271.0% | -6062.1% | ||
| Latest Twelve Months | -1366.5% | -181.7% | -70.6% | -5387.2% | -225.1% | -6062.1% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 0.6x | -7.2x | -0.4x | 1.1x | -2.5x | -6.0x | ||
| Price / LTM Sales | 6.5x | 20.0x | 0.8x | 104.4x | 5.9x | 180.2x | ||
| LTM P/E Ratio | -0.5x | -11.0x | -0.8x | -1.9x | -2.7x | -4.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.8x | 6.5x | 104.4x | |||||
| Historical LTM P/S Ratio | 180.2x | 551.5x | 828.7x | |||||
| Selected Price / Sales Multiple | 179.9x | 189.4x | 198.9x | |||||
| (x) LTM Sales | 1 | 1 | 1 | |||||
| (=) Equity Value | 249 | 262 | 275 | |||||
| (/) Shares Outstanding | 1,356.5 | 1,356.5 | 1,356.5 | |||||
| Implied Value Range | 0.18 | 0.19 | 0.20 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.18 | 0.19 | 0.20 | 0.21 | ||||
| Upside / (Downside) | -13.7% | -9.1% | -4.6% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FATE | CAPR | FBIO | CATX | PSTV | NWBO | |
| Value of Common Equity | 87 | 433 | 43 | 145 | 35 | 288 | |
| (/) Shares Outstanding | 114.6 | 45.7 | 27.6 | 74.1 | 33.9 | 1,356.5 | |
| Implied Stock Price | 0.76 | 9.48 | 1.54 | 1.96 | 1.02 | 0.21 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.76 | 9.48 | 1.54 | 1.96 | 1.02 | 0.21 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |